• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Can Botulinum Toxin Injections Reduce Pelvic Muscle Pain?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Up to 23% of chronic pelvic pain may be atributable to myofascial pain
    • Sensitive pelvic floor muscles with trigger points | Associated with other significant pain disorders such as dyspareunia and interstitial cystitis
  • Onabotulinumtoxin A has been used to treat pain disorders, but data is limited regarding myofascial pelvic pain
  • Dessie et al. (AJOG, 2019) compared the effects of onabotulinumtoxin A versus placebo injections to the pelvic flood muscles of women with myofascial pain

METHODS:

  • Double-blind, randomized, placebo-controlled trial (RCT)
  • Participants
    • ≥18 years
    • Myofascial pelvic pain including reporting both of the following
      • Pain ≥6 on a 10-point visual analog scale (VAS) ≥50% of the time
      • Pain on palpation ≥6 on the VAS in ≥1 of 6 pelvic floor muscle groups
  • Groups randomized to the following
    • Pelvic floor injection of 200 units of onabotulinumtoxin A
    • Pelvic floor injection of 20 mL of saline
  • Physical therapy
    • Begun 4 weeks after injection for 8 weeks duration
  • Validated questionnaires
    • Baseline and then 2, 4, and 12 weeks after injection
  • Urogynecologist (blinded to treatment) examined patient with palpation of pelvic floor muscle groups
  • Primary outcome
    • Change in participant-reported pain on palpation of the most painful pelvic floor muscle from baseline to 2 weeks
  • Secondary outcomes: Changes in the following
    • Pain at 4 and 12 weeks | Overall self-assessment based on VAS | Quality-of-life questionnaires | Medication use | Physiotherapy compliance | Adverse events
  • Statistical analysis
    • 24 participants per arm required to have 80% power to detect primary outcome effect (additional patients recruited to account for participant drop out)

RESULTS:

  • 59 women were randomized
    • 30 participants in intervention group | 29 participants in placebo group
  • No significant differences between the onabotulinumtoxin A and placebo groups were found for the following
    • Change in participant-reported pain at 2 weeks
    • Participant-reported pain on palpation for any muscle group at 4 or 12 weeks
  • Participants in the intervention group were more likely to report their symptoms were improved at 4 weeks (p=0.03; based on the Patient Global Impression of Improvement index)
  • Adverse events at 2 weeks
    • Most common: Constipation in both arms, with 10.1% reporting de novo constipation with no statistical difference between groups
    • 22% of the intervention group reported urinary incontinence (4 in the intervention group and 1 in placebo group)
    • Other complications occurred in <4 participants

CONCLUSION:

  • Onabotulinumtoxin A injections to the pelvic floor did not result in improved pelvic pain outcomes on clinical exam, although some women did report improved symptoms

Learn More – Primary Sources:

A randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA trigger point injections for myofascial pelvic pain

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

What AbobotulinumtoxinA Dosage Is Best for Treating Overactive Bladder?
Do Botulinum Toxin Injections Prevent Migraines?
Cochrane Review: What is the Evidence for the Prevention of Migraines Using Botulinum toxins?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site